Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
EBMT 2022
This year, we shared exclusive feature articles across a range of disease areas, but which were most popular with our readers?🤔📖
🩸Time to check out our Top 5:
1) Practical Considerations for GPRC5D-directed Therapies in #MultipleMyeloma
2) VEXAS syndrome and MDS: exploring…
The biggest #ASH25 takeaways, discussed by global experts 💡 🌍
Join our Post ASH 2025 Highlights webinar series 💻 🩸
🗓️ 22nd Jan - 11th Feb
Covering: #AML (@Daver_Leukemia) , Multiple #Myeloma, #CLL, #Lymphoma (@DrJasonWestin), #MPNs (@harrisoncn1), #MDS (@Dr_AmerZeidan)…
🚨Initial results of MajesTEC-3: Tec-Dara versus DPd/DVd in patients with R/R #MultipleMyeloma
This data was hot news at #ASH25, and we caught up with Luciano Costa (@End_myeloma) to bring you all the details!🎥
Watch here: 👉
#MMSM #Myeloma #HemOnc…
Initial results from MajesTEC-3: Tec-Dara versus DPd/DVd in patients with R/R multiple myeloma
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, presents the first interim results of the MajesTEC-3...
ow.ly
At #ASH25, @DrMDavids of @DanaFarber shared insight into the MAVRiC trial, an upcoming Ph II trial investigating the efficacy of retreatment with AV in pts with CLL/SLL who have relapsed after first-line finite-duration therapy with a BTKi plus ven-based combination.
Watch here:…
#ASH25 | Aniket Bankar (@neuf_sang_23) of @pmcancercentre discusses patient-reported outcomes from the Phase III VERIFY study of rusfertide or placebo plus current standard of care in patients with #PolycythemiaVera:
🎥
#MPNsm #HemOnc #CTSM #TrialUpdate
Patient-reported outcomes in the Phase III VERIFY trial of rusfertide for polycythemia vera
Aniket Bankar, MD, Princess Margaret Cancer Centre, Toronto, Canada, discusses the patient-reported outcomes from the Ph...
ow.ly
EBMT 2022
This year, we shared exclusive feature articles across a range of disease areas, but which were most popular with our readers?🤔📖
🩸Time to check out our Top 5:
1) Practical Considerations for GPRC5D-directed Therapies in #MultipleMyeloma
2) VEXAS syndrome and MDS: exploring…
The biggest #ASH25 takeaways, discussed by global experts 💡 🌍
Join our Post ASH 2025 Highlights webinar series 💻 🩸
🗓️ 22nd Jan - 11th Feb
Covering: #AML (@Daver_Leukemia) , Multiple #Myeloma, #CLL, #Lymphoma (@DrJasonWestin), #MPNs (@harrisoncn1), #MDS (@Dr_AmerZeidan)…
🚨Initial results of MajesTEC-3: Tec-Dara versus DPd/DVd in patients with R/R #MultipleMyeloma
This data was hot news at #ASH25, and we caught up with Luciano Costa (@End_myeloma) to bring you all the details!🎥
Watch here: 👉
#MMSM #Myeloma #HemOnc…
Initial results from MajesTEC-3: Tec-Dara versus DPd/DVd in patients with R/R multiple myeloma
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, presents the first interim results of the MajesTEC-3...
ow.ly
At #ASH25, @DrMDavids of @DanaFarber shared insight into the MAVRiC trial, an upcoming Ph II trial investigating the efficacy of retreatment with AV in pts with CLL/SLL who have relapsed after first-line finite-duration therapy with a BTKi plus ven-based combination.
Watch here:…
#ASH25 | Aniket Bankar (@neuf_sang_23) of @pmcancercentre discusses patient-reported outcomes from the Phase III VERIFY study of rusfertide or placebo plus current standard of care in patients with #PolycythemiaVera:
🎥
#MPNsm #HemOnc #CTSM #TrialUpdate
Patient-reported outcomes in the Phase III VERIFY trial of rusfertide for polycythemia vera
Aniket Bankar, MD, Princess Margaret Cancer Centre, Toronto, Canada, discusses the patient-reported outcomes from the Ph...
ow.ly
